硼替佐米为主的化疗方案治疗58例多发性骨髓瘤患者的临床分析

《硼替佐米为主的化疗方案治疗58例多发性骨髓瘤患者的临床分析》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、硼替佐米为主的化疗方案治疗58例多发性骨髓瘤患者的临床分析咸阳市屮心医院陕西咸阳712000摘要：目的：分析以硼替佐米为主的化疗方案治疗多发性骨髓瘤患者的临床疗效,为更加有效安全的治疗多发性骨髓瘤提供方案。方法：选取咸阳市屮心医院2012年3月至2015年3月被诊断为多发性骨髓瘤患者58例,采用以硼替佐米为主,联合地塞米松、沙利度胺以及表柔比星的化疗方案进行治疗。分析记录患者治疗前后骨髓内浆细胞量、血清M蛋口量以及β2-微球蛋口的变化情况。结果：结果显示在58例患者中48例是初治患者，10例为多次复发患者。其屮初治

2、患者治疗有效率81.25%；多次复发患者治疗有效率为70.00%。58例患者均采用硼替佐米为主的化疗，与治疗前比较，其骨髓内浆细胞量、血清M蛋口量以及β2-微球蛋白的数值显著降低，差异具有统计学意义(P<0.05)o结论：采用以硼替佐米为主的化疗方案治疗多发性骨髓瘤，在选用初治、复发及难治患者可以有效提高临床疗效，提高患者生存质量，与此同时，密切监测患者的不良反应也尤为重要。关键词：硼替佐米；多发性骨髓瘤；沙利度胺；临床疗效【中图分类号】R733・3【文献标识码】AClinicalAnalysisof58Ca

3、sesofPatientswithMultipleMyelomaBortezomibBasedChemotherapyZhangGuangyingThecentralhospitalofXianyangCity,Xianyang712000,ChinaAbstract:objective:toanalysisisgivenprioritytowithboronforMrMtheclinicalefficacyofchemotherapyfortreatmentofmultiplemyelomapatients,toprovi

4、demoreeffectivesecurityinthetreatmentofmultiplemyeloma.Methods:selectionofxianyangcenterhospitalinMarch2012toMarch2015werediagnosedwith58patientswithmultiplemyeloma,usewithboronforriceisgivenpriorityto,combineddexamethasone,Sallydegreesofamineandepirubicinchemother

5、apyregimensfortreatment.Analysisofpatientsbeforeandaftertreatmentintheamountofplasmacellsinthebonemarrow,Mproteinandserumbeta2-microglobulinchanges.Results:theresultsshowedthatin58patientswith48casesistreatedfirstpatients,10casesofrecurreneeinpatientswithmanytimes.

6、Theinitialtreatmentinpatientswitheffectiveratewas81.25%;Manypatientswithrecurrenttreatmenteffectiveratewas70.00%.Adoptboronfor58patientswithriceisgivenprioritytochemotherapy,comparedwithbeforetreatment,theplasmacellsinbonemarrow,serumMproteinamountandthevalueofbeta

7、2-microglobulinsignificantlyreduced,statisticallysignificantdifferenee（P<0.05）.Conclusion:usewithboronforricebasedchemotherapyregimenformultiplemyeloma,governance,recurrentandrefractorypatientsintheearlyselectioncaneffectivelyimprovetheclinicalcurativeeffect,imp

8、rovethequalityofsurvival,atthesametime,closemonitoringofpatientswithadversereactionsareparticularlyimportant.Keywords:Bortezomib;Multiplemyeloma;